RU2015140720A - Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой - Google Patents
Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой Download PDFInfo
- Publication number
- RU2015140720A RU2015140720A RU2015140720A RU2015140720A RU2015140720A RU 2015140720 A RU2015140720 A RU 2015140720A RU 2015140720 A RU2015140720 A RU 2015140720A RU 2015140720 A RU2015140720 A RU 2015140720A RU 2015140720 A RU2015140720 A RU 2015140720A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- construct
- dna
- pharmaceutical composition
- dna construct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Конструкт ДНК для иммуномодуляции, состоящий из частично одноцепочечной, гантелеобразной цепи остатков ДНК с ковалентно закрытой структурой, дважды содержащей частично гидролизованную последовательность ДНК SEQ ID NO: 1.
2. Конструкт по п. 1, где одноцепочечная петля содержит три CG-мотива.
3. Конструкт по любому из пп. 1 или 2, где каждый CG-мотив с обеих сторон фланкирован дезокситимидином.
4. Конструкт по любому из пп. 1 и 2, где одноцепочечная петля имеет содержание пиримидина по меньшей мере 50%.
5. Конструкт по п. 4, где пиримидин представляет дезокситимидин.
6. Конструкт по любому из пп. 1 и 2, где по меньшей мере один нуклеотид модифицирован функциональной группой, выбираемой из группы, состоящей из карбоксильной, аминной, амидной, альдиминной, кетальной, ацетальной, сложного эфира, простого эфира, дисульфидной, тиоловой и альдегидной группы.
7. Конструкт по п. 5, где модифицированный нуклеотид может быть связан с соединением, выбираемым из группы, состоящей из пептидов, белков, углеводов, антител, липидов, мицелл, везикул, синтетических молекул, полимеров, микрочастиц, частиц металлов, наночастиц или твердой фазы.
8. Фармацевтическая композиция, содержащая конструкт ДНК по любому из пп. 1 и 2.
9. Фармацевтическая композиция по п. 8, дополнительно содержащая химиотерапевтический агент.
10. Вакцина, содержащая конструкт ДНК по любому из пп. 1 и 2.
11. Вакцина по п. 10, где конструкт ДНК используется в качестве адъюванта.
12. Применение конструкта ДНК по любому из пп. 1 и 2, фармацевтической композиции по п. 8 или вакцины по п. 10 для лечения рака или аутоиммунных заболеваний.
13. Применение конструкта ДНК по любому из пп. 1 и 2, фармацевтической композиции по п. 8 или вакцины по п. 10 для модуляции иммунной системы.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1402847.6 | 2014-02-18 | ||
| GB1402847.6A GB2523187A (en) | 2014-02-18 | 2014-02-18 | Covalently closed non-coding immunomodulatory DNA construct |
| PCT/EP2015/053396 WO2015124614A1 (en) | 2014-02-18 | 2015-02-18 | Covalently closed non-coding immunomodulatory dna construct |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015140720A true RU2015140720A (ru) | 2017-03-29 |
| RU2668387C2 RU2668387C2 (ru) | 2018-09-28 |
Family
ID=50440342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015140720A RU2668387C2 (ru) | 2014-02-18 | 2015-02-18 | Некодирующий иммуномодулирующий конструкт днк с ковалентно закрытой структурой |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10280424B2 (ru) |
| EP (1) | EP2999787B1 (ru) |
| JP (1) | JP6067893B2 (ru) |
| KR (1) | KR101831713B1 (ru) |
| CN (1) | CN105264074A (ru) |
| AU (1) | AU2015220911B2 (ru) |
| BR (1) | BR112015025748A2 (ru) |
| CA (1) | CA2908522A1 (ru) |
| DK (1) | DK2999787T3 (ru) |
| ES (1) | ES2634002T3 (ru) |
| GB (1) | GB2523187A (ru) |
| HK (1) | HK1216758A1 (ru) |
| MX (1) | MX2015014190A (ru) |
| RU (1) | RU2668387C2 (ru) |
| SG (1) | SG11201508108YA (ru) |
| WO (1) | WO2015124614A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| GB2523187A (en) * | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| LU92821B1 (en) * | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| GB2542425A (en) * | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| CN111278510A (zh) | 2017-08-31 | 2020-06-12 | 莫洛根股份公司 | 用于调节肿瘤微环境的tlr-9激动剂 |
| US20230323343A1 (en) * | 2020-01-31 | 2023-10-12 | Tyris Therapeutics, S.L. | Closed linear dna with modified nucleotides |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
| JP2005535627A (ja) * | 2002-06-25 | 2005-11-24 | シティ・オブ・ホープ | アジュバント不含ペプチド・ワクチン |
| CA2517675A1 (en) * | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
| OA13278A (en) | 2003-10-30 | 2007-01-31 | Coley Pharm Gmbh | C-Class oligonucleotide analogs with enhanced immunostimulatory potency. |
| BRPI0418157A (pt) | 2003-12-30 | 2007-04-17 | Mologen Ag | terapêutica de tumores alogênicos |
| CN1918293A (zh) * | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子 |
| WO2006015560A1 (de) * | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
| CN101490257A (zh) * | 2006-05-11 | 2009-07-22 | 莫洛根股份公司 | 用于免疫刺激的多聚体 |
| WO2010039137A1 (en) | 2008-10-02 | 2010-04-08 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| EP2246433A1 (de) | 2009-04-30 | 2010-11-03 | Mologen AG | Concatemere zur Immunmodulation |
| GB2523187A (en) * | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
-
2014
- 2014-02-18 GB GB1402847.6A patent/GB2523187A/en not_active Withdrawn
-
2015
- 2015-02-18 SG SG11201508108YA patent/SG11201508108YA/en unknown
- 2015-02-18 BR BR112015025748A patent/BR112015025748A2/pt not_active IP Right Cessation
- 2015-02-18 JP JP2015563141A patent/JP6067893B2/ja not_active Expired - Fee Related
- 2015-02-18 EP EP15706416.3A patent/EP2999787B1/en not_active Not-in-force
- 2015-02-18 WO PCT/EP2015/053396 patent/WO2015124614A1/en active Application Filing
- 2015-02-18 CA CA2908522A patent/CA2908522A1/en not_active Abandoned
- 2015-02-18 ES ES15706416.3T patent/ES2634002T3/es active Active
- 2015-02-18 CN CN201580000576.0A patent/CN105264074A/zh active Pending
- 2015-02-18 MX MX2015014190A patent/MX2015014190A/es unknown
- 2015-02-18 AU AU2015220911A patent/AU2015220911B2/en not_active Ceased
- 2015-02-18 KR KR1020157028152A patent/KR101831713B1/ko active IP Right Grant
- 2015-02-18 DK DK15706416.3T patent/DK2999787T3/en active
- 2015-02-18 RU RU2015140720A patent/RU2668387C2/ru not_active IP Right Cessation
- 2015-02-18 US US14/899,601 patent/US10280424B2/en active Active
-
2016
- 2016-04-20 HK HK16104520.3A patent/HK1216758A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016526373A (ja) | 2016-09-05 |
| JP6067893B2 (ja) | 2017-01-25 |
| ES2634002T3 (es) | 2017-09-26 |
| DK2999787T3 (en) | 2017-08-07 |
| CN105264074A (zh) | 2016-01-20 |
| KR20150130425A (ko) | 2015-11-23 |
| MX2015014190A (es) | 2015-12-11 |
| BR112015025748A2 (pt) | 2017-10-10 |
| SG11201508108YA (en) | 2015-10-29 |
| HK1216758A1 (zh) | 2016-12-02 |
| WO2015124614A1 (en) | 2015-08-27 |
| KR101831713B1 (ko) | 2018-02-23 |
| EP2999787A1 (en) | 2016-03-30 |
| US10280424B2 (en) | 2019-05-07 |
| AU2015220911A1 (en) | 2015-10-15 |
| RU2668387C2 (ru) | 2018-09-28 |
| GB2523187A (en) | 2015-08-19 |
| US20160348114A1 (en) | 2016-12-01 |
| CA2908522A1 (en) | 2015-08-27 |
| GB201402847D0 (en) | 2014-04-02 |
| AU2015220911B2 (en) | 2017-02-02 |
| EP2999787B1 (en) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015140720A (ru) | Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой | |
| WO2015037000A8 (en) | Vstm5 polypeptides and uses thereof for treatment of cancer, infectious diseases and immune related diseases | |
| WO2017024317A3 (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
| PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| RU2015146614A (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
| RU2019124678A (ru) | Слитый белок pd1-41bbl и способы его применения | |
| EP3563865A3 (en) | Prostate-associated antigens and vaccine-based immunotherapy regimens | |
| CL2013003406A1 (es) | Compuestos derivados de dolastatina unidos a aminoacidos no naturales; procedimiento de preparacion; composiciones farmaceuticas, útiles en el tratamiento del cancer de mamas. | |
| IN2014CN03029A (ru) | ||
| EP3725801A3 (en) | Amino diacids containing peptide modifiers | |
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| WO2013096866A3 (en) | Processes using vlps with capsids resistant to hydrolases | |
| AR088963A1 (es) | Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina | |
| WO2013098802A3 (en) | Solid phase peptide synthesis via side chain attachment of hydroxyl amino acids | |
| WO2016209978A3 (en) | Thiol-ene based peptide stapling and uses thereof | |
| WO2015011694A3 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
| BR112016012306A2 (pt) | peptídeos ricos em prolina para proteção contra s. pneumoniae | |
| EA201490032A1 (ru) | Лиофилизированные препараты fgf-18 | |
| AR100745A1 (es) | Nanopartículas de quitosano cargadas con antígeno para inmunoterapia | |
| EA201991702A1 (ru) | Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты | |
| WO2016022958A3 (en) | Tick-associated virus sequences and uses thereof | |
| WO2015038915A3 (en) | Compositions and methods using capsids resistant to hydrolases | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. | |
| BR112013025892A2 (pt) | método para tratar condições relacionadas com ifn-alfa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170606 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20180518 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190219 |